Department of Laboratory Sciences, Faculty of Paramedicine, AJA University of Medical Sciences, Tehran, Iran.
Department of Cardiology, Faculty of medicine, AJA University of Medical Sciences, Tehran, Iran.
Arch Med Res. 2020 Feb;51(2):167-172. doi: 10.1016/j.arcmed.2020.01.009. Epub 2020 Mar 6.
Recent studies have shown that complement C1q tumor necrosis factor related proteins (CTRPs) such as adiponectin, have different regulatory roles on the cardiovascular system. CTRP2 is the most similar to adiponectin and one of the best characterized beneficial adipokines important in the regulation of whole body metabolism. However, there were no studies about the relationship between CTRP2 and Coronary artery disease (CAD). This study aimed to evaluate the serum CTRP2 levels in patient with Coronary artery disease. In this study, a total of 82 participants who underwent vascular angiography were included. All of subjects were male. According to their coronary angiography results, all participants were divided into CAD group (n = 42) and control group (n = 40). Serum CTRP2 levels were determined quantitatively with enzyme-linked immunosorbent assay (ELISA). Our study for the first time showed that the CTRP2 levels were higher in CAD patients (1.79 ± 1.46 ng/mL) compared to control subjects (1.08 ± 0.78 ng/mL; p = 0.001). The levels of CTRP2 also were positively correlated with severity of CAD (r = 0.356, p = 0.001). In addition, logistic regression analysis indicated that CTRP2 had an independent association with the risk of CAD (OR [CI] = 3.366 [1.605-7.060]; p = 0.001). Increased levels of CTRP2 in CAD patients were independently associated with the progression of the CAD, it might be regarded as a novel biomarker for assessing the risk of CAD; however, more study is required in this regard.
最近的研究表明，补体 C1q 肿瘤坏死因子相关蛋白（CTRPs），如脂联素，对心血管系统有不同的调节作用。CTRP2 与脂联素最为相似，是调节全身代谢的最佳特征之一的有益脂肪因子之一。然而，目前还没有关于 CTRP2 与冠状动脉疾病（CAD）之间关系的研究。本研究旨在评估冠心病患者血清 CTRP2 水平。
在这项研究中，共纳入 82 名接受血管造影的参与者。所有受试者均为男性。根据他们的冠状动脉造影结果，所有参与者分为 CAD 组（n=42）和对照组（n=40）。用酶联免疫吸附试验（ELISA）定量测定血清 CTRP2 水平。我们的研究首次表明，CAD 患者的 CTRP2 水平（1.79±1.46ng/mL）高于对照组（1.08±0.78ng/mL；p=0.001）。CTRP2 水平与 CAD 的严重程度呈正相关（r=0.356，p=0.001）。此外，逻辑回归分析表明，CTRP2 与 CAD 的风险有独立关联（OR[CI]=3.366[1.605-7.060]；p=0.001）。
CAD 患者中 CTRP2 水平升高与 CAD 的进展独立相关，它可能被视为评估 CAD 风险的新型生物标志物；然而，这方面还需要更多的研究。
